Is Newself a reliable and well rated online company for providing injection tirzepitide

1. What supporters and NewSelf itself claim — convenience, pricing, and clinical access

NewSelf advertises a telehealth pathway delivering a GLP‑1 blend including tirzepatide, filled by state‑licensed 503A pharmacies and prescribed by board‑certified clinicians, operating in 48 states plus Puerto Rico, with a stated price point of about $449/month and free overnight shipping but a three‑month commitment and various fees; the company is presented as LegitScript certified and publishes pharmacy and physician partners to support legitimacy ^{[1] [4]}. These claims position NewSelf as an affordable access route for patients seeking tirzepatide-like therapy outside manufacturer channels, and the company’s transparency about pharmacy partners and certification is a factual indicator of an operational telepharmacy model rather than an anonymous seller ^{[1] [4]}.

2. What customers say — mixed reviews and recurring service complaints

Independent review aggregators show a mixed-to-poor customer experience: multiple platforms report an overall rating in the low‑to‑mid 2s or a 2.9/5 average across a small number of reviews, with recurring themes of fast shipping and helpful staff from some users contrasted with allegations of unapproved medication deliveries, poor customer service interactions, refund and billing disputes, and packaging or temperature‑control concerns; the company has responded to some complaints but dissatisfaction persists among a subset of reviewers ^{[5] [2]}. These verified user reports document operational inconsistencies that matter for injectable medications where cold‑chain integrity and accurate dosing are clinically critical, making service reliability a material consideration for patient safety ^[5].

3. Independent trust and web‑safety signals — probably legit but caution warranted

Third‑party web‑trust analyses assign NewSelf a medium‑low risk trust score (around 61) and note a valid SSL certificate and safe payment options, but also flag low traffic ranking and keywords associated with scam concerns; these indicators suggest the site is not obviously fraudulent yet exhibits surface‑level risk signals and limited third‑party validation, warranting further vetting ^[3]. Combining that assessment with LegitScript certification and disclosed licensed pharmacy partners yields a mixed picture: operational legitimacy on paper but reputational and transparency gaps in practice, meaning additional checks — pharmacy licensure verification and state board listings for prescribers — are prudent before enrollment ^{[1] [3]}.

4. Clinical and regulatory context — compounded tirzepatide is not FDA‑approved

Several sources note a critical clinical and regulatory reality: compounded formulations of tirzepatide and other GLP‑1 blends are not FDA‑approved, and compounded drugs carry inherent variability and regulatory limitations; outcomes reported online are anecdotal and influenced by patient factors like genetics, lifestyle, and comorbidities, so clinical supervision and informed consent are essential ^{[1] [6]}. Manufacturer and pharmacy channels differ: Eli Lilly expanded self‑pay options for FDA‑approved tirzepatide products through defined pharmacy solutions, but compounded alternatives bypass brand‑specific approvals — this distinction affects legal frameworks, insurance coverage, and perceived safety profiles, making the therapy’s regulatory status a key decision driver ^[6].

5. Bottom line for patients deciding whether NewSelf is “reliable and well rated”

Factually, NewSelf operates a telehealth‑to‑pharmacy model with published partners and LegitScript certification, and some customers report good experiences; however, independent review aggregates, trust‑score flags, and multiple user complaints yield a mixed reliability record rather than a consistently well‑rated reputation ^{[1] [5] [3]}. Patients should verify pharmacy licensure and prescriber credentials, confirm cold‑chain and shipment practices for injectable products, compare manufacturer self‑pay direct channels versus compounded options, and consult their healthcare provider before starting therapy; these steps address both documented service issues and the clinical implications of using non‑FDA‑approved compounded tirzepatide ^{[4] [1] [5]}.